Determinants for urinary and plasma isoflavones in humans after soy intake

Nutrition and Cancer

Volumn 50, Issue 2, 2004, Pages 141-154

  Franke, Adrian A ^a   Custer, Laurie J ^a   Hundahl, Scott A ^b  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b Queen's Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DAIDZEIN; GENISTEIN; GLYCITEIN; GLYCOSIDE; ISOFLAVONE; PUERARIN; SOYBEAN PROTEIN;

ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; FEMALE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; MALE; MICROBIAL ACTIVITY; SIMULATION; SOYBEAN; STOMACH JUICE; URINALYSIS; URINARY EXCRETION;

AREA UNDER CURVE; GENISTEIN; GLUCOSIDES; HUMANS; INTESTINAL ABSORPTION; ISOFLAVONES; MALE; SOY FOODS;

BACTERIA (MICROORGANISMS); GLYCINE MAX;

EID: 12744272008     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5002_3     Document Type: Article

References (92)

1. Stark A and Madar Z: Phytoestrogens: a review of recent findings. J Pediatr Endocrinol Metab 15, 561-572, 2002.
2. Friedman M and Brandon DL: Nutritional and health benefits of soy proteins. J Agric Food Chem 49, 1069-1086, 2001
3. Washam C: Soy and breast cancer. Environ Health Perspect 108, A370, 2000.
4. Messina M and Barnes S: The role of soy products in reducing risk of cancer. J Natl Cancer Inst 83, 541-546, 1991.
5. Lee HP, Gourley L, Duffey SW, Esteve J, Lee J, et al.: Dietary effects on breast-cancer risk in Singapore. Lancet 337, 1197-1200, 1991.
6. Dai Q, Franke AA, Jin F, Shu X-O, Hebert JR, et al.: Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. Cancer Epidemiol Biomarkers Prev 11, 815-821, 2002.
7. Adlercreutz H and Mazur W: Phyto-estrogens and Western diseases. Ann Med 29, 95-120, 1997.
8. Barnes S: Evolution of the health benefits of soy isoflavones. Proc Soc Exp Biol Med 217, 386-392, 1998.
9. Setchell KDR: Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68 (suppl. 6), 1333S-1346S, 1998.
10. Gilani GS and Anderson JB: Phytoestrogens and Health, Champaign, IL: AOCS Press, 2002.
11. Franke AA, Hankin JH, Yu MC, Maskarinec G, Low SH, et al.: Isoflavone levels in soy foods consumed by multiethnic populations in Singapore and Hawaii. J Agric Food Chem 47, 977-986, 1999.
12. Tsukamoto C, Shimada S, Igita K, Kudou S, Kokubun M, et al.: Factors affecting isoflavone content in soybean seeds: changes in isoflavones, saponins, and composition of fatty acids at different temperatures during seed development . J Agric Food Chem 43, 1184-1192, 1995.
13. Barnes S, Kirk M, and Coward L: Isoflavones and their conjugates in soy foods: extraction conditions and analysis by HPLC-mass spectrometry. J Agric Food Chem 42, 2466-2474, 1994.
14. Wang H and Murphy PA: Isoflavone content in commercial soybean foods. J Agric Food Chem 42, 1666-1673, 1994.
15. Sfakianos J, Coward L, Kirk M, and Barnes S: Intestinal uptake and biliary excretion of the isoflavone genistein in the rat: evidence for its enterohepatic circulation. J Nutr 127, 1260-1268, 1997.
16. Piskula MK, Yamakoshi J, and Iwai Y: Daidzein and genistein but not their glucosides are absorbed from the rat stomach. FEBS Lett 447, 287-291, 1999.
17. Andlauer W, Kolb J, and Furst P: Isoflavones from tofu are absorbed and metabolized in the isolated rat small intestine. J Nutr 130, 3021-3027, 2000.
18. Hendrich S: Bioavailability of isoflavones. J Chromatogr B Analyt Technol Biomed Life Sci 777, 203-210, 2002.
19. Setchell KD, Brown NM, Desai PB, Zimmer-Nechimias L, Wolfe B, et al.: Bioavailability, disposition, and dose- response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr 133, 1027-1035, 2003.
20. Walle T, Otake Y, Walle UK, and Wilson FA: Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr 130, 2658-2661, 2000.
21. Sesink ALA, O'Leary KA, and Hollman PCH: Quercetin glucuronides but not glucosides are present in human plasma after consumption of quercetin-3- glucoside or quercetin-4′-glucoside. J Nutr 131, 1938-1941, 2001.
22. Hollman PCH, de Vries JHM, van Leeuwen SD, Mengelers MJB, and Katan MB: Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 62, 1276-1282, 1995.
23. Franke AA and Custer LJ: High-performance liquid chromatography assay of isoflavonoids and coumestrol from human urine. J Chromatogr B 662, 47-60, 1994.
24. Fanti P, Sawaya PB, Custer LJ, and Franke AA: Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients. J Am Soc Nephrol 40, 382-389, 1999.
25. Xu X, Harris KS, Wang HJ, Murphy PA, and Hendrich S: Unavailability of soybean isoflavones depends upon gut microflora in women. J Nutr 125, 2307-2315, 1995.
26. Karr SC, Lampe JW, Hutchins AM, and Slavin JL: Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein consumption. Am J Clin Nutr 66, 46-51, 1997.
27. Setchell KDR, Faughnan MS, Avades T, Zimmer-Nechemias L, Brown NM, et al.: Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am J Clin Nutr 77, 411-419, 2003.
28. Zubik L and Meydani M: Bioavailability of soybean isoflavones from aglycon and glucoside forms in American women. Am J Clin Nutr 77, 1459-1465, 2003.
29. Busby MG, Jeffcoat AR, Bloedon LT, Koch MA, Black T, et al.: Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 75, 126-136, 2002.
30. Yamamoto S, Sobue T, Sasaki S, Kobayashi M, Arai Y, et al.: Validity and reproducibility of a self-administered food-frequency questionnaire to assess the isoflavone intake in a Japanese population in comparison with dietary records and blood and urine isoflavones. J Nutr 131, 2741-2747, 2001.
31. Arai Y, Uehara M, Sato Y, Kimira M, Eboshida A, et al.: Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol 10, 127-135, 2000.
32. Franke AA, Yu MC, Maskarinec G, Fanti P, Zheng W, et al: Phytoestrogens in human biomatrices including breast milk. Biochem Soc Trans 27, 308-318, 1999.
33. Benlhabib E, Baker JI, Keyler DE, and Singh AK: Composition, red blood cell uptake, and serum protein binding of phytoestrogens extracted from commercial kudzu-root and soy preparations. J Med Food 5, 109-123, 2002.
34. Yu BS, Yan X, Zhen GB, and Rao YP: RP-HPLC determination of puerarin in Chinese traditional medicinal preparations containing pueraria. J Pharm Biomed Anal 30, 843-849, 2002.
35. Kim DH, Yu KU, Bae EA, and Han MJ: Metabolism of puerarin and daidzin by human intestinal bacteria and their relation to in vitro cytotoxicity. Biol Pharm Bull 21, 628-630, 1998.
36. Kim DH, Jung EA, Sohng IS, Han JA, Kim TH, et al.: Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch Pharm Res 21, 17-23, 1998.
37. Franke AA, Custer LJ, Wang W, and Shi SJ: HPLC analysis of isoflavonoids and other phenolic agents from foods and from human fluids. Proc Soc Exp Biol Med 217, 263-273, 1998.
38. Franke AA, Custer LJ, Wilkens LR, Le Marchand L, Nomura ANs, et al.: Liquid chromatographic analysis of dietary phytoestrogens from human urine and blood. J Chromatogr B 777, 43-57, 2002.
39. Blair RM, Appt SE, Franke AA, and Clarkson TB: Treatment with antibiotics reduces plasma equol concentration in cynomolgus monkeys (Macaca fascicularis). J Nutr 133, 2262-2267, 2003.
40. Cline JM, Franke AA, Register TC, Golden DL, and Adams MR: Effects of dietary isoflavone aglycons on the reproductive tract of male and female mice. Toxicol Pathol 32, 91-99, 2004.
41. Schouten WR and Gordon PH: Preoperative and postoperative management. In Principles and Practice of Surgery for the Colon, Rectum, and Anus, Gordon PH and Nivatvongs S, eds., St. Louis, MO: Quality Medical Publishing, 1992, pp. 119-137.
42. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, and Talalay P: Human metabolism and excretion of chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiol Biomarkers Prev 7, 1091-1100, 1998.
43. Gillatt PN, Palmer RC, Smith PLR, and Walters CL: Susceptibilities of drugs to nitrosation under simulated gastric conditions. Food Chem Toxicol 23, 849855, 1985.
44. Franke AA, Custer LJ, Cerna CM, and Narala KK: Quantitation of phytoestrogens in legumes by HPLC. J Agric Food Chem 42, 1905-1913, 1994.
45. Lampe JW, Karr SC, Hutchins AM, and Slavin JL: Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 217, 335-339, 1998.
46. Setchell KDR, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, et al.: Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131, 1362S-1375S, 2001.
47. Setchell KDR, Brown NM, and Lydeking-Olsen E: The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 132, 3577-3584, 2002.
48. Morton MS, Arisaka O, Miyake N, Morgan LD, and Evans BA: Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 132, 3168-3171, 2002.
49. Lampe JW, Skor HE, Li S, Wähälä K, Howald WN, et al.: Wheat bran and soy protein feeding do not alter urinary excretion of the isoflavan equol in premenopausal women. J Nutr 131, 740-744, 2001.
50. Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, and Bowey EA: Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 36, 27-32, 2000.
51. Lu LJW and Anderson KE: Sex and long-term soy diets affect the metabolism and excretion of soy isoflavonens in humans. Am J Clin Nutr 68, 1400S-1504S, 1998.
52. Duncan AM, Merz-Demlow BE, Xu X, Phipps WR, and Kurzer MS: Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9, 581-586, 2000.
53. Lund TD, Munson DJ, Haldy ME, Setchell KD, Lephart ED, et al.: Equol Is a Novel Anti-Androgen that Inhibits Prostate Growth and Hormone Feedback. Biol Reprod 70, 1188-1195, 2004.
54. Piskula MK: Factors affecting flavonoid absorption. Biofactors 12, 175-180, 2000.
55. Murota K, Shimizu S, Miyamoto S, Izumi T, Obata A, et al.: Unique uptake and transport of isoflavone aglycons by human intestinal caco-2 cells: comparison of isoflavonoids and flavonoids. J Nutr 132, 1956-1961, 2002.
56. Setchell KD, Brown NM, Zimmer-Nechemias L, Brashear WT, Wolfe BE, et al.: Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 76, 447-453, 2002.
57. Axelson M and Setchell KD: The excretion of lignans in rats - evidence for an intestinal bacterial source for this new group of compounds. FEBS Lett 123, 337-342, 1981.
58. Xu X, Wang H-J, Murphy PA, Cook L, and Hendrich S: Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women. J Nutr 124, 825-832, 1994.
59. Ritchie MR, Morton MS, Deighton N, Blake A, and Cummings JH: Plasma and urinary phyto-oestrogens as biomarkers of intake: validation by duplicate diet analysis. Br J Nutr 91, 447-457, 2004.
60. Grace PB, Taylor JI, Low YL, Luben RN, Mulligan AA, et al.: Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol Biomarkers Prev 13, 698-708, 2004.
61. Fanti P, Stephenson TJ, Kaariainen IM, Rezkalla B, Tsukamoto Y, et al.: Soy food intake and serum levels of soy isoflavones in Japanese, Thai and North American end-stage renal failure patients on chronic hemodialyis therapy. Nephrol Dial Transplant 18, 1862-1868, 2003.
62. Silbernagl S and Despopoulos A: Taschenatlas der Physiologie, 2nd ed. New York: Thieme, 1983.
63. Nichols RL and Condon RE: Antibiotic preparation of the colon: failure of commonly used regimens. Surg Clin North Am 51, 223-231, 1971.
64. Nichols RL and Condon RE: Preoperative preparation of the colon. Surg Gynecol Obstet 132, 323-337, 1971.
65. Schneider H, Schwiertz A, Collins MD, and Blaut M: Anaerobic transformation of quercetin-3-glucoside by bacteria from the human intestinal tract. Arch Microbiol 171, 81-91, 1999.
66. Haeberlin B, Rubas W, Nolen III HW, and Friend DR: In vitro evaluation of dexamethasone-β-D-glucuronide for colon-specific drug delivery. Pharm Res 10, 1553-1562, 1993.
67. Nichols RL, Condon RE, and Gorbach SL: Alteration of the intestinal flora following antimicrobial therapy. Rev Surg 29, 53-54, 1972.
68. Nichols RL, Condon RE, Gorbach SL, and Nyhus LM: Efficacy of preoperative antimicrobial preparation of the bowel. Ann Surg 176, 227-232, 1972.
69. Kodner IJ, Fry RD, Fleshman JW, and Birnbaum EH: Colon, rectum, and anus. In Principles of Surgery, 6th ed., Schwartz SI, Shires GT, Spencer FC, and Husser WC (eds). New York: McGraw-Hill, p. 1191, 1994.
70. 2 is a major pathway. FASEB J. 15, A1098, 2001.
71. Setchell KDR, Borriello SP, Gordon H, Lawson AM, Harkness R, et al.: Lignan formation in man - microbial involvement and possible roles in relation to cancer. Lancet 317, 4-7, 1981.
72. Kilkkinen A, Stumpf K, Pietinen P, Valsta LM, Tapanainen H, et al.: Determinants of serum enterolactone concentration. Am J Clin Nutr 73, 1094-1100, 2001.
73. Booth AN, Murray CW, Jones FT, and DeEds F: The metabolic fate of rutin and quercetin in the animal body. J Biol Chem 223, 251-257, 1956.
74. Walle T, Walle UK, and Halushka PV: Carbon dioxide is the major metabolite of quercetin in humans. J Nutr 131, 2648-2652, 2001.
75. Ueno T, Uchiyama S, and Kikuchi N: The role of intestinal bacteria on biological effects of soy isoflavones in humans. J Nutr 132, 594S (abstract), 2002.
76. Bokkenheuser VD and Winter J: Hydrolysis of flavonoids by human intestinal bacteria. In Plant Flavonoids in Biology and Medicine II, Cody V, Middleton E, Harborne JB, and Beretz A, (eds). New York: A.R. Liss, pp. 143-145, 1988.
77. Winter J, Moore LH, Dowell VR, and Bokkenheuser VD: C-ring cleavage of flavonoids by human intestinal bacteria. Appl Environ Microbiol 55, 1203-1208, 1989.
78. Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJC, et al.: Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver -glucosidase activity. FEBS Lett 436, 71-75, 1998.
79. Day AJ, Canada FJ, Diaz JC, Kroon PA, McLaughlan RFCB, et al.: Dietary flavonoids and isoflavonoid glycosides are hydrolysed by the lactase site of lactase phloridzin hydrolase. FEBS Lett 468, 166-170, 2000.
80. Marsh MN and Riley SA: Digestion and Absorption of Nutrients and Vitamins. In Gastrointestinal and Liver Disease Digestion and Absorption of Nutrients and Vitamins, Vol. 2, 6th ed. In Feldman M, Scharschmidt BF, Sleisenger M, and Klein (eds). Philadelphia: W.B. Saunders, 1998, pp. 1471-1501.
81. Walgren RA, Lin JT, Kinne RK, and Walle T: Cellular uptake of dietary flavonoid quercetin 4′-beta-glucoside by sodium-dependent glucose transporter SGLT1. J Pharmacol Exp Ther 294, 837-843, 2000.
82. Walle UK, French KL, Walgren RA, and Walle T: Transport of genistein-7-glucoside by human intestinal CACO-2 cells: potential role for MRP2. Res Commun Mol Pathol Pharmacol 103, 45-56, 1999.
83. Andlauer W, Kolb J, and Furst P: Absorption and metabolism of genistin in the isolated rat small intestine. FEBS Lett 475, 127-130, 2000.
84. Tobin PJ, Dodds HM, Clarke S, Schnitzler M, Rivory LP, et al.: The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours: The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. J Pharmacol Exp Ther 10, 1977-1979, 649-655, 2003.
85. Walgren RA, Karnaky KJ Jr, Lindenmayer GE, and Walle T: Efflux of dietary flavonoid quercetin 4′-β-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance- associated protein-2. J Pharmacol Exp Ther 294, 830-836, 2000.
86. Izumi T, Piskula MK, Osawa S, Obata A, Tobe K, et al.: Soy isoflavone aglycons are absorbed faster and in higher amounts than their glucosides in humans. J Nutr 130, 1695-1699, 2000.
87. Hutchins AM, Slavin JL, and Lampe JW: Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products. J Am Diet Assoc 95, 545-551, 1995.
88. Richelle M, Pridmore-Merten S, Bodenstab S, Enslen M, and Offord EA: Hydrolysis of isoflavone glycosides to aglycons by beta-glycosidase does not alter plasma and urine isoflavone pharmacokinetics in postmenopausal women. J Nutr 132, 2587-2592, 2002.
89. Chang HC, Churchwell MI, Delclos KB, Newbold RR, and Doerge DR: Mass spectrometric determination of Genistein tissue distribution in diet-exposed Sprague-Dawley rats. J Nutr 130, 1963-1970, 2000.
90. Franke AA and Custer LJ: Daidzein and genistein concentration in human milk after soy consumption. Clin Chem 42, 955-964, 1996.
91. Zheng W, Dai Q, Custer LJ, Shu X-O, Wen W-Q, et al.: Urinary excretion of isoflavones and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 8, 35-40, 1999.
92. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, et al.: Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 132, 552S-558S, 2002.